WT-161

• Description :

  WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM[1]. WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) [2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Beta-lactamase; HDAC

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/WT-161.html

• Concentration :

  10mM

• Purity :

  98.04

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(N/N=C/C1=CC=C(N(C2=CC=CC=C2)C3=CC=CC=C3)C=C1)CCCCCCC(NO)=O

• Molecular Formula :

  C27H30N4O3

• Molecular Weight :

  458.55

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Hideshima T, et al. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016 Nov 15;113 (46) :13162-13167.|[2]Severin Lechner, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022 Apr 28.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC1; HDAC2; HDAC3; HDAC6; HDAC8

• CAS Number :

  [1206731-57-8]